Stockreport

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients [Yahoo! Finance]

MEI Pharma, Inc.  (MEIP) 
Last mei pharma, inc. earnings: 2/6 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.meipharma.com
PDF – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Development of [Read more]